Livzon Pharmaceutical (01513.HK): Leuprorelin Acetate Microspheres for Injection 11.25mg (3-month formulation) received the "Drug Supplementary Application Approval Notice"

Zhito Finance APP News: Livzon Pharmaceutical (01513.HK) announced that recently, its controlling subsidiary Shanghai Livzon Pharmaceutical Co., Ltd. (Shanghai Livzon) received the "Drug Supplementary Application Approval Notice" (Certificate No.: 2026B06648) approved and issued by the National Medical Products Administration. The leuprorelin acetate microspheres for injection 11.25mg (3-month dosage form) produced by Shanghai Livzon has been approved for marketing.